The intersection of testosterone deficiency and prostate cancer survivorship affects thousands of men annually, yet treatment approaches have remained conservative due to theoretical concerns about cancer recurrence. This paradigm may be shifting as accumulating evidence challenges long-held assumptions about testosterone's role in prostate cancer progression.
The British Society for Sexual Medicine's comprehensive analysis reveals that testosterone replacement therapy demonstrates an acceptable safety profile across multiple clinical scenarios, including men under active surveillance, post-surgery patients, and those who have completed radiation therapy. The review synthesizes data showing no significant increase in biochemical recurrence rates or disease progression when TRT is administered to carefully selected hypogonadal men with prostate cancer histories. These findings align with the saturation model of prostate cancer biology, which suggests that once testosterone reaches physiological levels, further increases do not proportionally drive cancer growth.
This evidence represents a meaningful evolution in understanding testosterone's oncological safety profile, though it builds incrementally on existing research rather than overturning established principles. The consensus emphasizes that successful implementation requires sophisticated patient selection criteria, multidisciplinary care coordination, and intensive monitoring protocols. For the growing population of prostate cancer survivors experiencing debilitating symptoms of hypogonadism—including severe fatigue, mood disorders, and sexual dysfunction—these findings offer hope for improved quality of life. However, the authors appropriately note gaps in long-term follow-up data, suggesting this remains an area requiring continued research and cautious clinical application until more definitive longitudinal studies emerge.